CHAPTER 1 INTRODUCTION
1.1 Key Benefits
1.2 Key Market Segments
1.3 Research Methodology
1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market beyond what to expect by 2025 ($Million)
2.1.1 Moderate growth scenario
2.1.2 Rapid growth scenario
2.1.3 Diminishing growth scenario
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Evolution of Erythropoietin drugs
3.3 Erythropoietin Omega and Delta: pruned R&D pipeline drugs
3.4 Ethical considerations of erythropoietin drugs
3.5 Key findings
3.5.1 Top Factors Impacting for Global Erythropoietin Drugs Market
3.5.2 Top Investment Pockets for Global Erythropoietin Drugs Market
3.6 Value Chain Analysis
3.7 Key market player positioning (2014)
3.8 Product positioning for patented products (2014)
3.9 Clinical trials for EPO drug in neural diseases and wound healing
3.10 Competitive Intelligence on top three leaders (Amgen, J&J and Roche)
3.11 Market share analysis, 2013
3.12 Market dynamics
3.12.1 Drivers
3.12.1.1 Increasing number cases: including cancer,HIV, kidney disease and anaemia
3.12.1.2 Growing trends of commercialization for erythropoietin biosimilars
3.12.1.3 Readily available reimbursements and favorable government regulations
3.12.1.4 Increasing level of awareness about the benefits of EPO therapeutics
3.12.2 Restraints
3.12.2.1 Unaffordability of therapeutics
3.12.2.2 Longer duration of treatments
3.12.2.3 Adverse amount of side effects
3.12.3 Opportunities
3.12.3.1 Commercialization of darbepotin alfa biosimilar
3.12.3.2 Achieving Economies of scale across developed region with biosimilar version of EPO
CHAPTER 4 GLOBAL ERYTHROPOIETIN MARKET BY PRODUCTS
4.1 Epoetin-alfa
4.1.1 Historical Milestones
4.1.2 Commercial outlook
4.1.3 Approaches of clinical trials
4.1.4 Key market trends
4.1.5 Regulatory and reimbursement scenarios
4.1.6 Key growth factors and opportunities
4.1.7 Market size and forecast
4.2 Epoetin-beta
4.2.1 Historical Milestones
4.2.2 Approaches of clinical trials
4.2.3 Key market trends
4.2.4 Regulatory and reimbursement scenarios
4.2.5 Key growth factors and opportunities
4.2.6 Market size and forecast
4.3 Darbepoetin-alfa
4.3.1 Historical Milestones
4.3.2 Commercial outlook
4.3.3 Approaches of clinical trials
4.3.4 Key market trends
4.3.5 Regulatory and reimbursement scenarios
4.3.6 Key growth factors and opportunities
4.3.7 Market size and forecast
CHAPTER 5 GLOBAL ERYTHROPOIETIN MARKET BY APPLICATIONS
5.1 Anemia (Cancer and HIV treatment)
5.2 Kidney Disorders (ESRD and Dialysis)
5.3 Others (Neural Disease and Wound healing)
CHAPTER 6 GLOBAL ERYTHROPOIETIN MARKET BY GEOGRAPHY
6.1 North America
6.1.1 Key market trends
6.1.2 Reimbursement and regulations
6.1.3 Key growth factors and opportunities
6.1.4 Market size and forecast
6.2 Europe
6.2.1 Key market trends
6.2.2 Reimbursement and regulations
6.2.3 Key growth factors and opportunities
6.2.4 Market size and forecast
6.3 Asia-Pacific
6.3.1 Key market trends
6.3.2 Reimbursement and regulations
6.3.3 Key growth factors and opportunities
6.3.4 Market size and forecast
6.4 LAMEA
6.4.1 Key market trends
6.4.2 Reimbursement and regulations
6.4.3 Key growth factors and opportunities
6.4.4 Market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1 Amgen Inc.
7.1.1 Overview
7.1.2 Amgen Inc. snapshot
7.1.3 Financial performance
7.1.4 Operating Business Segment
7.1.5 SWOT analysis
7.2 Johnson and Johnson
7.2.1 Company overview
7.2.2 Johnson & Johnson snapshot
7.2.3 Operating Business Segment Overview
7.2.4 Financial performance
7.2.1 SWOT Analysis
7.3 Roche
7.3.1 Company overview
7.3.2 Roche Diagnostics snapshot
7.3.3 Operating Business Segment Overview
7.3.4 Financial performance
7.3.5 SWOT analysis of Roche Diagnostics
7.4 Hospira
7.4.1 Company overview
7.4.2 Hospira snapshot
7.4.3 Operating Business Segment Overview
7.4.4 Financial performance
7.4.5 SWOT analysis of Hospira
7.5 LG Life Sciences Ltd.
7.5.1 Company overview
7.5.2 LG Life Sciences Ltd. snapshot
7.5.3 Operating Business Segment Overview
7.5.4 Financial performance
7.5.5 SWOT analysis of LG Life Sciences Ltd.
7.6 Biocon
7.6.1 Company overview
7.6.2 Biocon snapshot
7.6.3 Operating Business Segment Overview
7.6.4 Financial performance
7.6.5 SWOT analysis of Biocon
7.7 Intas Pharmaceuticals
7.7.1 Company overview
7.7.2 Intas Pharmaceuticals snapshot
7.7.3 Operating Business Segment Overview
7.7.4 Financial performance
7.7.5 SWOT analysis of Intas Pharmaceuticals
7.8 Teva Pharmaceutical Industries Ltd.
7.8.1 Company overview
7.8.2 Teva Pharmaceutical Industries Ltd. snapshot
7.8.3 Operating Business Segment Overview
7.8.4 Financial performance
7.8.5 SWOT analysis of Teva Pharmaceutical Industries Ltd.
7.9 Ranbaxy Laboratories Ltd.
7.9.1 Company overview
7.9.2 Ranbaxy Laboratories Ltd. snapshot
7.9.3 Operating Business Segment Overview
7.9.4 Financial performance
7.9.5 SWOT analysis of Ranbaxy Laboratories Ltd.
7.10 Celltrion, Inc
7.10.1 Company overview
7.10.2 Celltrion, Inc. snapshot
7.10.3 Operating Business Segment Overview
7.10.4 Financial performance
7.10.5 SWOT analysis of Celltrion, Inc.